Market capitalization | $2.81m |
Enterprise Value | $1.88m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.23 |
P/S ratio (TTM) P/S ratio | 0.35 |
P/B ratio (TTM) P/B ratio | 0.93 |
Revenue growth (TTM) Revenue growth | -23.00% |
Revenue (TTM) Revenue | $8.05m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
1 Analyst has issued a forecast ReShape Lifesciences, Inc.:
1 Analyst has issued a forecast ReShape Lifesciences, Inc.:
Jun '24 |
+/-
%
|
||
Revenue | 8.05 8.05 |
23%
23%
|
|
Gross Profit | 5.43 5.43 |
11%
11%
|
|
EBITDA | -9.19 -9.19 |
49%
49%
|
EBIT (Operating Income) EBIT | -9.26 -9.26 |
52%
52%
|
Net Profit | -9.02 -9.02 |
74%
74%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ReShape Lifesciences Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. It operates through the following segments: Lap-Band, ReShape Vest and ReShape vBloc. The company was founded on December 2002 and is headquartered in San Clemente, CA.
Head office | United States |
CEO | Paul Hickey |
Employees | 31 |
Founded | 2002 |
Website | www.reshapelifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.